

26/F, HKRI Centre One, HKRI Taikoo Hui
288 Shimen Road (No. 1)
Shanghai 200041, P. R. China
T: (86-21) 5298-5488
F: (86-21) 5298-5492

20380 Town Center Lane, Suite 128
Cupertino, CA 95014, USA
T: +1 888 886 8168
F: +1 888 808 2168

August 12, 2024

CITIC Securities (Hong Kong) Limited

18/F, One Pacific Place
88 Queensway
Hong Kong

CLSA Limited

18/F, One Pacific Place
88 Queensway
Hong Kong

Deutsche Bank AG, Hong Kong Branch

Level 60, International Commerce Centre
1 Austin Road West, Kowloon
Hong Kong

CMB International Capital Limited

45/F, Champion Tower
3 Garden Road, Central
Hong Kong

Haitong International Securities Company Limited

22/F Li Po Chun Chambers
189 Des Voeux Road Central
Hong Kong

BOCI Asia Limited

26/F, Bank of China Tower
1 Garden Road, Central
Hong Kong

Livermore Holdings Limited

Unit 1214A, 12/F, Tower II Cheung Sha Wan Plaza
833 Cheung Sha Wan Road, Kowloon
Hong Kong

Re: TYK Medicines, Inc

Ladies and Gentlemen,

TYK Medicines, Inc together with its subsidiaries (the “Company”) have requested us to conduct a due diligence review on certain intellectual property matters regarding the Company. We are providing this letter pursuant to Section 2.1.1 of the Hong Kong Underwriting Agreement dated August 9, 2024 (the “Hong Kong Underwriting Agreement”) between the Company and the Hong Kong Underwriters and Section 2.1.1 of the International Underwriting Agreement to be dated on or around August 16, 2024 (the “International Underwriting Agreement”, together with the Hong Kong Underwriting Agreement, the “Underwriting Agreements”) between the Company and the International Underwriters, each in connection with the proposed Hong Kong Public Offering of the Company in the Hong Kong Stock Exchange. We act as special patent counsel to the Company and our representation has been limited to matters individually referred to us by the Company. There may be patent and related matters involving or impacting the Company of which we are unaware.

In connection with this letter, we have reviewed the statements included in the Prospectus (the “Disclosure Documents”) related to the Chinese and U.S. patents and patent applications listed in Appendix A attached hereto (the “Company Patents”), as well as the relevant Chinese and U.S. patent laws, which are made in the section titled “Risk Factors” under the heading “Risks Relating to Our Intellectual Property Rights”, and section titled “Business” under the heading “Intellectual Property” (collectively, the “Patent Statements”). Except with respect to the Patent Statements, we did not participate in the preparation of the Disclosure Documents, and we have not been consulted to advise on any other part of the Disclosure Documents. We have limited our review of the Disclosure Documents to the Patent Statements.

The purpose of our professional engagement was not to establish or confirm factual matters set forth in the Prospectus, and we have not undertaken any obligation to verify those factual matters. Accordingly, except to the extent of our opinions set forth in paragraphs A to H below, we are not passing upon and we assume no responsibility for the accuracy, completeness or fairness of the statements contained in or incorporated by reference into the Disclosure Documents.

Based on the foregoing and subject to the assumptions, qualifications, limitations and exceptions as stated in this letter, we advise you that:

- A. Nothing has come to our attention causing us to believe that any of the Patent Statements contains any untrue statement of material fact or fails to state any material fact necessary to make the statements therein not misleading, and, to our knowledge, all such statements are accurate and complete and present fairly the information therein.
- B. We have not become aware of any facts causing us to believe that the Company does not own or otherwise possess sufficient rights under all patent

rights that are currently employed by the Company in connection with their respective businesses, or that is necessary for the manufacture, importation, use or sale of its product candidates as described in the Disclosure Documents. We have not become aware of any facts causing us to believe that the Company does not own or have not obtained licenses for, or other rights to use, Company Patents described as being owned or licensed or used by them as described in the Disclosure Documents.

- C. We are not aware of any issued third-party patent rights that would be infringed by the manufacture, importation, use or sale by the Company of the Company's product candidates as described in the Disclosure Documents.
- D. To our knowledge, there is no claim, action, suit or proceeding pending or threatened against the Company alleging that the Company has infringed, misappropriated or otherwise violated any intellectual property rights of any third party. We have not become aware of any facts causing us to believe that the current or planned development and commercialization of the Company's product candidates, as described in the Disclosure Documents, would infringe any issued patents of any third party (it being understood that the opinion in this paragraph D is made without giving effect to any exemption under U.S. patent law or analogous foreign law to which the Company may be entitled (e.g., 35 U.S.C. Section 271(e)(1)). To our knowledge, the Company has not in respect of any patent received any notice of infringement of or conflict with any patent rights of others which, in either case, individually or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would have a material adverse effect on the Company.
- E. We have not become aware of any facts causing us to believe that the claims of any issued, unexpired patents owned by the Company are invalid and unenforceable under the patent laws of the People's Republic of China (solely for the purposes of this Scope of Intellectual Property Opinion, excluding Hong Kong, the Macau Special Administrative Region and the islands of Taiwan) and the United States.
- F. To our knowledge, there are no liens, encumbrances or security interests against any Company Patents for the benefit of a third party.
- G. To our knowledge, no claim, action, suit or proceeding (including any interference, reexamination, derivation, *inter partes* review, post grant review, opposition or other judicial or administrative proceeding) pertaining to the validity, enforceability or scope of any issued patents owned by the Company has been threatened or declared.
- H. To our knowledge, all applicable fees, surcharges and administrative procedures in relation to the maintenance of the Company Patents have been duly and properly paid and proceeded.

The opinions expressed herein are also subject to the following assumptions, limitations, qualifications and exceptions:

- (a) As to matters of fact, we have assumed the authenticity and validity of all records furnished to us by the Company and the information and certificates from various public officials, and we have not made any independent investigation or verification of the authenticity and validity of such records, information and certificates.
- (b) Whenever our opinions herein are qualified by the phrase “to our knowledge”, or “known to us” or similar phrases, the relevant knowledge is limited to the current actual knowledge after due inquiry of those attorneys presently in our firm who have performed substantive legal services for the Company in connection with this opinion.
- (c) Except as disclosed in a separate intellectual property due diligence report (the “IP DD Report”) issued by us on August 12, 2024 and our investigation in connection therewith, and except for our discussions with the Company and our review of documents provided by the Company in connection with the Hong Kong Public Offering, we have not made any independent investigation with respect to whether any of the Company Patents covers the Company’s product candidates as described in the Disclosure Documents, whether the Company Patents’ pending claims that cover its product candidates are assured to be granted, and whether any third party intellectual property rights constitute a hindrance for the manufacture, importation, use or sale of the Company’s product candidates as described in the Disclosure Documents.
- (d) The opinions expressed herein represent our reasonable judgment as to the matter of law addressed herein, based upon the facts presented, and are not, and shall not be construed as, a guarantee.
- (e) In acting as patent counsel to the Company, we have not been involved in the prosecution of the Company Patents. Any opinions set forth in this letter are limited to the patent laws of the People’s Republic of China and the patent laws of the United States, to the extent that the same may apply to or govern such matters addressed herein.

This letter is provided to you and your affiliates and legal advisers, in your capacity as the representative of the Hong Kong Underwriters and International Underwriters under the Hong Kong Underwriting Agreement and International Underwriting Agreement respectively and is solely for the benefit of the Underwriters in connection with the Hong Kong Public Offering. This letter may not be relied upon by you or the Underwriters for any other purpose. This letter may also not be provided to or relied upon by any other person or entity for any purpose, including, without limitation, any person or entity that acquires any securities of the Company from any of the Underwriters without our prior written consent, which we may withhold at our sole discretion. Notwithstanding these limitations, this letter can properly be furnished to

others (i) for the purpose of responding to a subpoena, order, requirement or request by any governmental, regulatory, self-regulatory or judicial authorities having competent jurisdiction over the Underwriters and (ii) for the purpose of seeking to establish any defence in any legal or regulatory proceeding or investigation arising out of the Hong Kong Public Offering, *provided* that JunHe LLP is given written notice in advance to the extent permitted by applicable laws.

This letter is limited to the matters expressly set forth herein, and no opinion has been implied, or may be inferred, beyond the matters expressly stated.

This letter is based on the law and facts as of the date hereof and we undertake no obligation or responsibility to update or supplement this letter to reflect any facts, circumstances, or changes in the law that may later occur or come to our attention.

Very truly yours,

JunHe LLP

JunHe LLP

APPENDIX A-PATENTS AND PATENT APPLICATIONS

(Updated as of August 2, 2024)

1.1 Patents and Patent Applications relating to TY-9591 (14 in total)

申请号	公开号	发明名称	国家/地区	权利人	申请日	过期日	法律状态
家族1-CN104140418B: 化合物及其用途							
2014104016047	CN104140418B	2-(2,4,5-取代苯胺)嘧啶衍生物及其用途	中国	浙江同源康医药股份有限公司	2014-08-15	2034-08-15	授权并有效
家族2-CN110013468B: 化合物的药物制剂							
2018100176859	CN110013468B	一种AZD9291氘代衍生物药物制剂	中国	浙江同源康医药股份有限公司	2018-01-09	2038-01-09	授权并有效
家族3-WO2018214886: 化合物的晶型、制备方法及其用途							
2018104956987	CN108558835A	一种氘代AZD9291的晶型、制备方法及其用途	中国	浙江同源康医药股份有限公司	2018-05-22	暂无	在审 ¹
16/615,771	US10882845B2	Crystal form of deuterated AZD9291, preparation method therefor, and use thereof	美国	TYK MEDICINES INC.	2018-05-22	2038-05-22	授权并有效

¹ 该中国专利申请已已获得授权，预计于2024年8月16日授权公告。

18804966.2	EP3647312B1	Crystal form of deuterated AZD9291, preparation method therefor, and use thereof	瑞士	TYK MEDICINES INC.	2018-05-22	2038-05-22	授权并有效
18804966.2	EP3647312B1	Crystal form of deuterated AZD9291, preparation method therefor, and use thereof	德国	TYK MEDICINES INC.	2018-05-22	2038-05-22	授权并有效
18804966.2	EP3647312B1	Crystal form of deuterated AZD9291, preparation method therefor, and use thereof	法国	TYK MEDICINES INC.	2018-05-22	2038-05-22	授权并有效
18804966.2	EP3647312B1	Crystal form of deuterated AZD9291, preparation method therefor, and use thereof	英国	TYK MEDICINES INC.	2018-05-22	2038-05-22	授权并有效
18804966.2	EP3647312B1	Crystal form of deuterated AZD9291, preparation method therefor, and use thereof	西班牙	TYK MEDICINES INC.	2018-05-22	2038-05-22	授权并有效
18804966.2	EP3647312B1	Crystal form of deuterated AZD9291, preparation method therefor, and use thereof	意大利	TYK MEDICINES INC.	2018-05-22	2038-05-22	授权并有效
2020-515809	JP6971390B2	Crystal form of deuterated AZD9291, preparation method therefor, and use thereof	日本	浙江同源康医药股份有限公司	2018-05-22	2038-05-22	授权并有效
家族4-CN110950847B: 化合物的晶型及其用途							
2018111276600	CN110950847B	氘代AZD9291化合物的新晶型及其用途	中国	浙江同源康医药股份有限公司	2018-09-27	2038-09-27	授权并有效

家族5-PCT/CN2023/128683: 药物组合物							
PCT/CN2023/128683	-	一种嘧啶类衍生物的药物组合物	PCT	浙江同源康医药股份有限公司	2023-10-31	暂无	未公开
2023114423871	-	一种嘧啶类衍生物的药物组合物	中国	浙江同源康医药股份有限公司	2023-10-31	暂无	未公开
家族6-CN2024105828924: 化合物的用途							
2024105828924	-	治疗EGFR敏感突变阳性非小细胞肺癌伴脑转移的表皮生长因子受体酪氨酸激酶抑制剂	中国	浙江同源康医药股份有限公司	2024-05-11	暂无	未公开

1.2 Patents and Patent Applications relating to TY-302 (2 in total)

申请号	公开号	发明名称	国家/地区	权利人	申请日	过期日	法律状态
家族1- CN104447739B: 化合物、制备方法及其应用							
201410623485X	CN104447739B	一种氘代Palbociclib衍生物、制备方法及应用	中国	浙江同源康医药股份有限公司	2014-11-07	2034-11-07	授权并有效
家族2- CN111718340A: 化合物的晶型、制备方法及其应用							
2019102110314	CN111718340A	氘代Palbociclib化合物的晶型、制备方法及应用	中国	浙江同源康医药股份有限公司	2019-03-20	暂无	在审

1.3 Patents and Patent Applications relating to TY-2136b (25 in total)

申请号	公开号	发明名称	国家/地区	权利人	申请日	过期日	法律状态
家族1-WO2020224626: 化合物及其应用							
2020800044732	CN112867717B	用作激酶抑制剂的化合物及其应用	中国	浙江同源康医药股份有限公司 ²	2020-05-07	2040-05-07	授权并有效
17/521,153	US20220089603 A1	Compound used as kinase inhibitor and application thereof	美国	TYK MEDICINES INC.	2020-05-07	暂无	在审
2021/09737	ZA202109737B	Compound used as kinase inhibitor and application thereof	南非	TYK MEDICINES INC.	2020-05-07	2040-05-07	授权并有效
202127055413	IN453914B	Compound used as kinase inhibitor and application thereof	印度	TYK MEDICINES INC.	2020-05-07	2040-05-07	授权并有效
202193062	EA045833B1	Compound used as kinase inhibitor and application thereof	亚美尼亚	TYK MEDICINES INC.	2020-05-07	2040-05-07	授权并有效
202193062	EA045833B1	Compound used as kinase inhibitor and application thereof	阿塞拜疆	TYK MEDICINES INC.	2020-05-07	2040-05-07	授权并有效
202193062	EA045833B1	Compound used as kinase inhibitor and application thereof	白俄罗斯	TYK MEDICINES INC.	2020-05-07	2040-05-07	授权并有效
202193062	EA045833B1	Compound used as kinase inhibitor and application thereof	吉尔吉斯斯坦	TYK MEDICINES INC.	2020-05-07	2040-05-07	授权并有效
202193062	EA045833B1	Compound used as kinase inhibitor and application thereof	哈萨克斯坦	TYK MEDICINES INC.	2020-05-07	2040-05-07	授权并有效

² 根据浙江同源康与丽珠医药签订的《专利转让及技术独占许可协议》，浙江同源康有义务将该中国专利转让给丽珠医药。

202193062	EA045833B1	Compound used as kinase inhibitor and application thereof	俄罗斯联邦	TYK MEDICINES INC.	2020-05-07	2040-05-07	授权并有效
202193062	EA045833B1	Compound used as kinase inhibitor and application thereof	塔吉克斯坦	TYK MEDICINES INC.	2020-05-07	2040-05-07	授权并有效
202193062	EA045833B1	Compound used as kinase inhibitor and application thereof	土库曼斯坦	TYK MEDICINES INC.	2020-05-07	2040-05-07	授权并有效
2020270303	AU2020270303B2	Compound used as kinase inhibitor and application thereof	澳大利亚	TYK MEDICINES INC.	2020-05-07	2040-05-07	授权并有效
10-2021-7040056	KR1020220007111A	Compound used as kinase inhibitor and application thereof	韩国	TYK MEDICINES INC.	2020-05-07	暂无	在审
20802185.7	EP3967696A1	Compound used as kinase inhibitor and application thereof	欧洲	TYK MEDICINES INC.	2020-05-07	暂无	在审
287908	IL287908A	Compound used as kinase inhibitor and application thereof	以色列	TYK MEDICINES INC.	2020-05-07	暂无	在审
11202112381V	SG11202112381VA	Compound used as kinase inhibitor and application thereof	新加坡	TYK MEDICINES INC.	2020-05-07	暂无	在审
112021022255-3	BR112021022255A2	Compound used as kinase inhibitor and application thereof	巴西	TYK MEDICINES INC.	2020-05-07	暂无	在审
MX/a/2021/013576	MX2021013576A	Compound used as kinase inhibitor and application thereof	墨西哥	TYK MEDICINES INC.	2020-05-07	暂无	在审
3,142,088	CA3142088C	Compound used as kinase inhibitor and application thereof	加拿大	TYK MEDICINES INC.	2020-05-07	2040-05-07	授权并有效
2021-566283	JP7420403B2	Compound used as kinase inhibitor and application thereof	日本	TYK MEDICINES INC.	2020-05-07	2040-05-07	授权并有效

62022050752.4	HK40063463A	Compound used as kinase inhibitor and application thereof	中国香港	TYK MEDICINES INC. ³	2020-05-07	暂无	在审 ⁴
J/6942	MOJ006942C	Compound used as kinase inhibitor and application thereof	中国澳门	TYK MEDICINES INC. ⁵	2020-05-07	2040-05-07	授权并有效
家族2- PCT/CN2023/134036: 晶体、药物组合物及其制备方法和应用							
PCT/CN2023/134036	-	晶体、药物组合物及其制备方法和应用	PCT	浙江同源康医药股份有限公司; 郑州同源康医药有限公司	2023-11-24	暂无	未公开
2023115904629	-	晶体、药物组合物及其制备方法和应用	中国	浙江同源康医药股份有限公司; 郑州同源康医药有限公司	2023-11-24	暂无	未公开

1.4 Other Patents and Patent Applications (145 in total)

申请号	公开号	国家/地区	权利人	申请日	过期日	法律状态
CN104140387家族: N-叔丁氧羰基-吡啶芳香醚/芳杂环醚类化合物的制备方法						

³ 根据浙江同源康与丽珠医药的《专利转让及技术独占许可协议》，浙江同源康有义务将该香港专利申请转让给丽珠医药。

⁴ 该申请指定专利当局为欧专局。

⁵ 根据浙江同源康与丽珠医药的《专利转让及技术独占许可协议》，浙江同源康有义务将该澳门专利转让给丽珠医药。

2013106423490	CN104140387B	中国	郑州同源康医药有限公司； 浙江同源康医药股份有限公司	2013-11-29	2033-11-29	授权并有效
CN104140393家族：N-芳环/芳杂环叔丁醇酯类化合物的制备方法						
2013106677745	CN104140393B	中国	郑州同源康医药有限公司； 浙江同源康医药股份有限公司	2013-12-10	2033-12-10	授权并有效
CN106967064家族：氘代Palbociclib衍生物、制备方法及应用						
2017101987122	CN106967064B	中国	浙江同源康医药股份有限公司	2017-03-29	2037-03-29	授权并有效
CN106986871家族：氘代Palbociclib的晶型及其制备方法和应用						
201710198725X	CN106986871B	中国	浙江同源康医药股份有限公司	2017-03-29	2037-03-29	授权并有效
CN108467385家族：氘代奥斯替尼衍生物及其应用						
2018106717745	CN108467385A	中国	浙江同源康医药股份有限公司	2018-06-26	暂无	在审
CN108689994家族：ALK激酶抑制剂的化合物及其应用						
2018107205941	CN108689994A	中国	浙江同源康医药股份有限公司	2018-06-30	暂无	在审
CN111848677家族：ALK激酶抑制剂化合物的晶型、制备方法及应用						
2019103519662	CN111848677B	中国	浙江同源康医药股份有限公司	2019-04-29	2039-04-29	授权并有效
WO2020233641家族：RET激酶抑制剂的化合物及其应用						
2020800329385	CN113784963B	中国	浙江同源康医药股份有限公司	2020-05-20	2040-05-20	授权并有效
17/613,311	US20220233513A1	美国	TYK MEDICINES INC.	2020-05-20	暂无	在审

2020280699	AU2020280699B2	澳大利亚	TYK MEDICINES INC.	2020-05-20	2040-05-20	授权并有效
20810190.7	EP3974422A1	欧洲	TYK MEDICINES INC.	2020-05-20	暂无	在审
2021-569540	JP2022534067A	日本	TYK MEDICINES INC.	2020-05-20	暂无	在审
J/8087	-	中国澳门	浙江同源康医药股份有限公司	2020-05-20	暂无	未公开
WO2021098883家族：EGFR激酶抑制剂的化合物及其应用						
2020113256098	CN112824420B	中国	浙江同源康医药股份有限公司	2020-11-23	2040-11-23	授权并有效
17/764,903	US20230026840A1	美国	TYK MEDICINES INC.	2020-11-23	暂无	在审
2020385527	AU2020385527B2	澳大利亚	TYK MEDICINES INC.	2020-11-23	2040-11-23	授权并有效
WO2021129841家族：RET激酶抑制剂的化合物及其应用						
2020115665107	CN113045569B	中国	浙江同源康医药股份有限公司	2020-12-25	2040-12-25	授权并有效
17/789,115	US20230095530A1	美国	TYK MEDICINES INC.	2020-12-25	暂无	在审
2020410900	AU2020410900A1	澳大利亚	TYK MEDICINES INC.	2020-12-25	暂无	在审
WO2021164793家族：激酶抑制剂的化合物及其应用						
2020101025251	CN113278012B	中国	郑州同源康医药有限公司； 浙江同源康医药股份有限公司	2020-02-19	2040-02-19	授权并有效
17/787,940	US20230089014A1	美国	TYK MEDICINES (ZHENGZHOU), INC. TYK MEDICINES INC.	2021-04-16	暂无	在审
WO2021180238家族：激酶抑制剂的化合物及其应用						

2021800139366	CN115175902B	中国	郑州同源康医药有限公司； 浙江同源康医药股份有限公司	2021-03-15	2041-03-15	授权并有效
17/911,138	US20230150975A1	美国	TYK MEDICINES (ZHENGZHOU), INC. TYK MEDICINES INC.	2021-03-15	暂无	在审
21768468.7	EP4119553A1	欧洲	TYK MEDICINES (ZHENGZHOU), INC. TYK MEDICINES INC.	2021-03-15	暂无	在审
WO2021233133家族：RET激酶抑制剂的化合物及其应用						
2021104972229	CN113698390B	中国	浙江同源康医药股份有限公司	2021-05-07	2041-05-07	授权并有效
17/926,846	US20230234954A1	美国	TYK MEDICINES INC.	2021-05-07	暂无	在审
J/6733	MOJ006733C	中国澳门	TYK MEDICINES INC.	2021-05-07	2041-05-07	授权并有效
2021276206	AU2021276206A1	澳大利亚	TYK MEDICINES INC.	2021-05-07	暂无	在审
10-2022-7044406	KR1020230015944A	韩国	TYK MEDICINES INC.	2021-05-07	暂无	在审
21808095.0	EP4155304A1	欧洲	TYK MEDICINES INC.	2021-05-07	暂无	在审
3,179,612	CA3179612A1	加拿大	TYK MEDICINES INC.	2021-05-07	暂无	在审
2022-571184	JP2023525933A	日本	TYK MEDICINES INC.	2021-05-07	暂无	在审
110116639	TWI782523B	中国台湾	TYK MEDICINES INC.	2021-05-07	2041-05-07	授权并有效
62023078288.5	HK40090211A	中国香港	TYK MEDICINES INC.	2021-05-07	暂无	在审 ⁶

⁶ 该申请指定专利当局为欧洲专利局。

WO2022017533家族：CDK7激酶抑制剂的化合物及其应用						
202110845318X	CN113717157A	中国	浙江同源康医药股份有限公司	2021-07-26	暂无	在审 ⁷
18/006,493	US20230295130A1	美国	TYK MEDICINES INC.	2021-07-26	暂无	在审
202327005981	IN202327005981A	印度	TYK MEDICINES INC.	2023-01-30	暂无	在审
10-2023-7006490	KR1020230043943A	韩国	TYK MEDICINES INC.	2021-07-26	暂无	在审
2021311686	AU2021311686A1	澳大利亚	TYK MEDICINES INC.	2021-07-26	暂无	在审
21845747.1	EP4186895A1	欧洲	TYK MEDICINES INC.	2021-07-26	暂无	在审
3,187,033	CA3187033A1	加拿大	TYK MEDICINES INC.	2021-07-26	暂无	在审
2023-504827	JP2023535746A	日本	TYK MEDICINES INC.	2021-07-26	暂无	在审
110127390	TWI804933B	中国台湾	TYK MEDICINES INC.	2021-07-26	2041-07-26	授权并有效
42022050755.2	HK40061853A	中国香港	TYK MEDICINES INC.	2021-07-26	暂无	在审 ⁸
WO2022095910家族：ROS1/NTRK/ALK激酶抑制剂化合物及其应用						
2020112164205	CN114437077B	中国	浙江同源康医药股份有限公司	2020-11-04	2040-11-04	授权并有效
42022061939.9	HK40072576A	中国香港	TYK MEDICINES INC.	2020-11-04	2040-11-04	授权并有效
J/7993	MOJ007993C	中国澳门	TYK MEDICINES INC.	2020-11-04	2040-11-04	授权并有效

⁷ 该中国专利申请已获得授权，预计于2024年8月16日授权公告。

⁸ 该申请指定专利当局为中国专利局。

110106655	TWI845819B	中国台湾	TYK MEDICINES INC.	2021-02-25	2040-11-04	授权并有效
18/251,729	US20240025908A1	美国	TYK MEDICINES INC.	2021-11-03	暂无	在审
WO2022258023家族: CDK激酶抑制剂的化合物及其应用						
2022800066726	CN116456987A	中国	郑州同源康医药有限公司; 浙江同源康医药股份有限公司	2022-06-09	暂无	在审
18/568,761	-	美国	TYK MEDICINES (ZHENGZHOU), INC. TYK MEDICINES INC.	2022-06-09	暂无	在审
111121472	TWI823420B	中国台湾	TYK MEDICINES (ZHENGZHOU), INC. TYK MEDICINES INC.	2022-06-09	2042-06-09	授权并有效
62023080910.0	HK40092805A	中国香港	TYK MEDICINES (ZHENGZHOU), INC. TYK MEDICINES INC.	2022-06-09	暂无	在审 ⁹
202317084524	-	印度	TYK MEDICINES (ZHENGZHOU), INC. TYK MEDICINES INC.	2022-06-09	暂无	未公开
2023-577147	JP2024523020A	日本	TYK MEDICINES (ZHENGZHOU), INC. TYK MEDICINES INC.	2022-06-09	暂无	未公开
2022289202	AU2022289202A1	澳大利亚	TYK MEDICINES (ZHENGZHOU), INC. TYK MEDICINES INC.	2022-06-09	暂无	在审
22819620.0	EP4353724A1	欧洲	TYK MEDICINES (ZHENGZHOU), INC. TYK MEDICINES INC.	2022-06-09	暂无	未公开
10-2024-7000908	KR1020240021239A	韩国	TYK MEDICINES (ZHENGZHOU), INC. TYK MEDICINES INC.	2022-06-09	暂无	未公开

⁹ 该申请指定专利当局为中国专利局。

3221997	CA3221997A1	加拿大	TYK MEDICINES (ZHENGZHOU), INC. TYK MEDICINES INC.	2022-06-09	暂无	在审
WO2023280283家族: SHP2抑制剂的化合物及其应用						
2022800066745	CN116323616A	中国	浙江同源康医药股份有限公司; 郑州同源康医药有限公司	2022-07-07	暂无	在审
111125565	TWI843142B	中国台湾	TYK MEDICINES INC. TYK MEDICINES (ZHENGZHOU), INC.	2022-07-07	2042-07-07	授权并有效
18/577,261	US20240190887A1	美国	TYK MEDICINES INC. TYK MEDICINES (ZHENGZHOU), INC.	2022-07-07	暂无	在审
WO2023016562家族: 多环类化合物及其用途						
111130445	TW202315613A	中国台湾	浙江同源康医药股份有限公司	2022-08-12	暂无	在审
2022800478482	CN117677608A	中国	浙江同源康医药股份有限公司	2022-08-12	暂无	在审
62024092214.1	-	中国香港	浙江同源康医药股份有限公司	2022-08-12	暂无	在审
18/682,183	-	美国	TYK MEDICINES INC.	2022-08-12	暂无	在审
2024-508668	-	日本	TYK MEDICINES INC.	2022-08-12	暂无	在审
10-2024-7008000	KR1020240046891A	韩国	TYK MEDICINES INC.	2022-08-12	暂无	在审
202417008980	IN202417008980A	印度	TYK MEDICINES INC.	2022-08-12	暂无	在审
2022855542.1	EP4385978A1	欧洲	TYK MEDICINES INC.	2022-08-12	暂无	在审
3228542	CA3228542A1	加拿大	TYK MEDICINES INC.	2022-08-12	暂无	在审

2022326724	AU2022326724A1	澳大利亚	TYK MEDICINES INC.	2022-08-12	暂无	在审
202393557	-	欧亚专利组织	TYK MEDICINES INC.	2022-08-12	暂无	未公开
WO2023078451家族：CDK7激酶抑制剂的化合物及其应用						
2022113872050	CN116082312A	中国	浙江同源康医药股份有限公司	2022-11-07	暂无	在审
111142421	TWI832539B	中国台湾	TYK MEDICINES INC.	2022-11-07	2042-11-07	授权并有效
42023078438.1	HK40089264A	中国香港	TYK MEDICINES INC.	2022-11-07	暂无	在审 ¹⁰
WO2023088385家族：EGFR蛋白降解的化合物及其用途						
2022114620979	CN116135852A	中国	浙江同源康医药股份有限公司	2022-11-17	暂无	在审
111144020	TW202329964A	中国台湾	TYK MEDICINES INC.	2022-11-17	暂无	在审
42023078441.5	HK40089265A	中国香港	TYK MEDICINES INC.	2022-11-17	暂无	在审 ¹¹
22894916.0		欧洲	浙江同源康医药股份有限公司	2022-11-17	暂无	未公开
2024-529488	-	日本	浙江同源康医药股份有限公司	2022-11-17	暂无	未公开
18/711,224	-	美国	浙江同源康医药股份有限公司	2022-11-17	暂无	未公开
10-2024-7019977	KR1020240109270A	韩国	TYK MEDICINES INC.	2022-11-17	暂无	在审
WO2023134692家族：多环类化合物及其用途						

¹⁰ 该申请指定专利当局为中国。

¹¹ 该申请指定专利当局为中国。

PCT/CN2023/07 1705	WO2023134692A1	PCT	浙江同源康医药股份有限公司	2023-01-10	¹²	-
2023100346352	CN116425757A	中国	浙江同源康医药股份有限公司	2023-01-10	暂无	在审
WO2023185468家族：激酶抑制剂的化合物及其应用						
PCT/CN2023/08 1557	WO2023185468A1	PCT	浙江同源康医药股份有限公司； 郑州同源康医药有限公司	2023-03-15	¹³	-
112109618	TWI841296B	中国台湾	TYK MEDICINES INC. TYK MEDICINES (ZHENGZHOU), INC.	2023-03-15	2043-03-15	授权并有效
2023246405		澳大利亚	浙江同源康医药股份有限公司 郑州同源康医药有限公司	2023-03-15	暂无	未公开
3,242,153		加拿大	浙江同源康医药股份有限公司 郑州同源康医药有限公司	2023-03-15	暂无	未公开
18/723,144		美国	浙江同源康医药股份有限公司 郑州同源康医药有限公司	2023-03-15	暂无	未公开
1120240128768		巴西	浙江同源康医药股份有限公司 郑州同源康医药有限公司	2023-03-15	暂无	未公开
P00202405727		印尼	浙江同源康医药股份有限公司 郑州同源康医药有限公司	2023-03-15	暂无	未公开
202380013526.0	CN117940421A	中国	浙江同源康医药股份有限公司； 郑州同源康医药有限公司	2023-03-15	暂无	在审

¹² PCT申请进入国家阶段的30个月期限为2024-07-13。

¹³ PCT申请进入国家阶段的30个月期限为2024-10-01。

2024-7020967		韩国	浙江同源康医药股份有限公司 郑州同源康医药有限公司	2023-03-15	暂无	未公开
23777843.6		欧洲	浙江同源康医药股份有限公司 郑州同源康医药有限公司	2023-03-15	暂无	未公开
202491351		欧亚专利组织	浙江同源康医药股份有限公司 郑州同源康医药有限公司	2023-03-15	暂无	未公开
202417048326		印度	浙江同源康医药股份有限公司 郑州同源康医药有限公司	2023-03-15	暂无	未公开
1-2024-05036		越南	浙江同源康医药股份有限公司 郑州同源康医药有限公司	2023-03-15	暂无	未公开
WO2023217156家族：多环类化合物及其用途						
PCT/CN2023/09 3095	WO2023217156A1	PCT	浙江同源康医药股份有限公司	2023-05-09	_14	-
2023105169566	CN117024405A	中国	浙江同源康医药股份有限公司	2023-05-09	暂无	在审
112143084	-	中国台湾	TYK MEDICINES INC.	2023-05-09	暂无	未公开
112117212	TW202400573A	中国台湾	TYK MEDICINES INC.	2023-05-09	暂无	在审
WO2024012543家族：CDK4激酶抑制剂的化合物及其应用						
PCT/CN2023/10 7308	WO2024012543A1	PCT	浙江同源康医药股份有限公司	2023-07-13	_15	-

¹⁴ PCT申请进入国家阶段的30个月期限为2024-11-09。

¹⁵ PCT申请进入国家阶段的30个月期限为2025-01-14。

202210833627X	CN117430597A	中国	浙江同源康医药股份有限公司	2022-07-14	暂无	在审
WO2024051702家族：CDK4激酶抑制剂的化合物及其应用						
PCT/CN2023/117094	WO2024051702A1	PCT	浙江同源康医药股份有限公司	2023-09-05	-	-
2023111388556	CN117645604A	中国	浙江同源康医药股份有限公司	2023-09-05	暂无	在审
42024093302.8	-	中国香港	浙江同源康医药股份有限公司	2023-09-05	暂无	未公开
112133722	TW202421129A	中国台湾	TYK MEDICINES INC.	2023-09-05	暂无	在审
2023111388560	-	中国	浙江同源康医药股份有限公司	2023-09-05	暂无	未公开
WO2024008083家族：用作CDK7激酶抑制剂的化合物及其应用						
PCT/CN2023/105733	WO2024008083A1	PCT	浙江同源康医药股份有限公司	2023-07-04	¹⁶	-
2022107880524	CN117384135A	中国	浙江同源康医药股份有限公司	2022-07-04	暂无	在审
42024090112	HK40101709A	中国香港	浙江同源康医药股份有限公司	2022-07-04	暂无	在审
PCT/CN2023/119440家族：嘧啶苯胺类化合物的晶型、制备方法及应用						
PCT/CN2023/119440	-	PCT	浙江同源康医药股份有限公司； 郑州同源康医药有限公司	2023-09-18	暂无	未公开
2023112021582	-	中国	浙江同源康医药股份有限公司； 郑州同源康医药有限公司	2023-09-18	暂无	未公开

¹⁶ PCT申请进入国家阶段的30个月期限为2025-01-04。

PCT/CN2023/130521家族：多环类化合物及其用途						
PCT/CN2023/130521	-	PCT	浙江同源康医药股份有限公司	2023-11-08	暂无	未公开
2023114807797	-	中国	浙江同源康医药股份有限公司	2023-11-08	暂无	未公开
PCT/CN2024/070435家族：用于预防和/或治疗神经退行性疾病的化合物						
2023110603288	-	中国	浙江同源康医药股份有限公司	2023-08-22	暂无	未公开
PCT/CN2024/070435	-	PCT	浙江同源康医药股份有限公司	2024-01-03	暂无	未公开
2024100076517	-	中国	浙江同源康医药股份有限公司	2024-01-03	暂无	未公开
42024094513.9	-	中国香港	浙江同源康医药股份有限公司	2024-01-03	暂无	未公开
113100281	-	中国台湾	TYK MEDICINES INC.	2024-01-03	暂无	未公开
WO2024051816A1家族：双环类PRMT5抑制剂						
PCT/CN2023/117714	WO2024051816A1	PCT	郑州同源康医药有限公司； 浙江同源康医药股份有限公司	2023-09-08	-	-
2022110976838	CN117658980A	中国	郑州同源康医药有限公司； 浙江同源康医药股份有限公司	2023-09-08	暂无	在审
PCT/CN2024/080957家族：三环类化合物						
PCT/CN2024/080957	-	PCT	浙江同源康医药股份有限公司； 郑州同源康医药有限公司	2024-03-11	暂无	未公开

其他专利/申请						
110119480	TW202237581A	中国台湾	TYK MEDICINES (ZHENGZHOU), INC.; TYK MEDICINES INC.	2021-05-28	暂无	在审
2023109503927	-	中国	上海同源康医药有限公司; 浙江同源康医药股份有限公司	2023-07-31	暂无	未公开
2023115568717	-	中国	上海同源康医药有限公司; 浙江同源康医药股份有限公司	2023-11-21	暂无	未公开
2023115483776	-	中国	浙江同源康医药股份有限公司	2023-11-20	暂无	未公开
PCT/CN2023/09 5142	-	PCT	浙江同源康医药股份有限公司	2023-05-18	暂无	未公开
PCT/CN2024/10 6225	-	PCT	浙江同源康医药股份有限公司	2024-07-18	暂无	未公开
2023109637300	-	中国	郑州同源康医药有限公司; 浙江同源康医药股份有限公司	2023-08-02	暂无	未公开
202311088252X	-	中国	郑州同源康医药有限公司; 浙江同源康医药股份有限公司	2023-08-28	暂无	未公开
2023112633979	-	中国	郑州同源康医药有限公司; 浙江同源康医药股份有限公司	2023-09-27	暂无	未公开
2024100333982	-	中国	浙江同源康医药股份有限公司	2024-01-09	暂无	未公开
PCT/CN2024/09 3652	-	PCT	浙江同源康医药股份有限公司	2024-05-16	暂无	未公开
2024102484436	-	中国	浙江同源康医药股份有限公司	2024-03-05	暂无	未公开

2024102727419	-	中国	浙江同源康医药股份有限公司 郑州同源康医药有限公司	2024-03-10	暂无	未公开
2024105154419	-	中国	郑州同源康医药有限公司 浙江同源康医药股份有限公司	2024-04-26	暂无	未公开
2024109680165	-	中国	浙江同源康医药股份有限公司 郑州同源康医药有限公司	2024-07-18	暂无	未公开
2024106093412	-	中国	浙江同源康医药股份有限公司	2024-05-16	暂无	未公开
2024106488366	-	中国	浙江同源康医药股份有限公司	2024-05-23	暂无	未公开
2024108434089	-	中国	浙江同源康医药股份有限公司	2024-06-26	暂无	未公开
2024105774182	-	中国	上海同源康医药有限公司 浙江同源康医药股份有限公司	2024-05-10	暂无	未公开
202411007747X	-	中国	浙江同源康医药股份有限公司	2024-07-25	暂无	未公开